

FRIDAY

18 September

MAIN HALL	HALL 2	HALL 3
08:00 - 09:30SESSION 22 The hidden problem of analytical interference – how to identify, investigate and prevent? (session by NFKK) Chair: Associate professor <i>Anna Linko-Parvinen</i> (Turku, FI)	08:00 - 09:30SESSION 23 Mass Spectrometry in Myeloma Chairs: Associate Professor <i>Anders Mønsted Abildgaard</i> (Aarhus DK) and Professor <i>Hans Christian Beck</i> (Odense DK)	08:00 - 09:30SESSION 24 ctDNA for guiding treatment decisions Chairs: Professor <i>Boe Sørensen</i> (Aarhus DK) and Professor <i>Claus Lindbjerg Andersen</i> (Aarhus DK)
08:00 - 08:30 Immunoglobulins and immunoassays: An introduction to common practical immunoassay challenges. Chief Physician <i>Johan Bjerner</i> Fürst Medical Laboratory, Oslo, Norway	08:00 - 08:20 Minimum Invasion, Maximum Insights - Ultra sensitive blood test for MRD monitoring in Multiple Myeloma Scientific Affairs Officer <i>Ian Ruigrok</i> Sebia, Lisses, France	08:00 - 08:40 NeoCircle: ctDNA monitoring in early breast cancer for evaluating neoadjuvant chemotherapy response and post-operative MRD Associate Professor <i>Lao Saal</i> Division of Oncology, CIRCE Women’s Cancer Research Center, Lund University, Sweden
08:30 - 09:00 Analytical interference in troponin assays Associate Professor <i>Saara Wittfooth</i> Department of Life Technologies, University of Turku, Turku, Finland	08:20 - 08:40 From gel electrophoresis to mass spectrometry: transitioning routine monoclonal protein monitoring to EXENT Dr. <i>Katie Horton</i> Binding Site Group Ltd., Birmingham, UK Measurement of monoclonal proteins is central to the diagnosis and monitoring of monoclonal gammopathies, including multiple myeloma. As deeper treatment responses demand greater analytical sensitivity, MALDI-TOF mass spectrometry has emerged as a powerful alternative to conventional methods. This presentation explores the transition to the EXENT™ system for routine laboratory testing.	08:40 - 09:05 Enhanced ctDNA detection in stage II and III colorectal cancer through whole genome sequencing with single-read error correction Phd student <i>Maria Hønholt Jørgensen</i> Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark Early detection of minimal residual disease is essential for optimizing the use of adjuvant chemotherapy. This talk presents a novel ultrasensitive tumor-informed whole-genome sequencing ctDNA assay that can detect, as early as 30 days after surgery, 66% of patients who subsequently develop recurrence. The assay performance supports the potential for ctDNA-guided treatment escalation and de-escalation.
09:00 - 09:30 Suspicion of Thyroid Interference - What Can the Laboratory Do? Chief Physician <i>Per Bjellerup</i> (Västerås SE) Centre of Clinical Research, Västerås, Sweden	08:40 - 09:05 Light chain-focused minimal residual disease detection in multiple myeloma: Integrating LC-MS-based proteomics into clinical practice Postdoctoral researcher <i>Nicolai B. Palstrøm</i> Department of Clinical Biochemistry, Odense University Hospital, Odense, Denmark	09:05 - 09:30 ctDNA as a tool for predicting treatment response to EGFR-targeted therapy in lung cancer Postdoctoral researcher, <i>Simone Stensgaard</i> Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus Denmark
	09:05 - 09:30	

A non-affinity-dependent high-resolution mass spectrometry method for detecting and typing monoclonal free light immunoglobulin chains

Hospital Chemist *Per Bengtson*
Department of Clinical Chemistry, Halland Hospital, Halland, Sverige

Measuring FLCs is important in the management of B-cell neoplasms. Established immunochemical methods relying on kappa/lambda ratios for monoclonality have limitations. We developed an MS-based method with simple, non-affinity sample preparation that detects isotypes, and semi-quantifies monoclonal monomeric and dimeric light chains, while also identifying post-translational modifications.

MAIN HALL

09:45 - 11:15 SESSION 25

Choosing wisely

Chairs: Clinical Director *Sidsel Rødgaard-Hansen* (Viborg, DK) and Senior Consultant Birgitte Sandfeld Paulsen (Aalborg, DK)

09:45 - 10:15

TBA

10:15 - 10:35

Hospital-Acquired Anemia

Professor *Henrik Løvendahl Jørgensen*

Department of Clinical Biochemistry, Amager-Hvidovre Hospital, Hvidovre, Denmark

The number of laboratory tests has increased steadily for decades, resulting in increasing cumulative diagnostic blood loss. Diagnostic phlebotomy is an important but often underestimated cause of hospital-acquired anaemia, which is associated with prolonged hospitalisation, increased transfusion requirements and poorer clinical outcomes. Optimising laboratory test patterns may therefore improve both patient safety and resource utilisation.

10:35 - 10:55

Update on Choosing wisely initiative in Medical Biochemistry, Norway

Consultant *Ragnhild V. Nome*
Department of Clinical Biochemistry, Oslo University Hospital, Oslo, Norway

HALL 2

09:45 - 11:15 SESSION 26

Career Paths in Clinical Biochemistry: Opportunities, Challenges, and Future Directions (session by YLKB)

Chairs: Dr. *Anne Lind Malte* (Aarhus, DK) and Dr. *Sine Voss David* (Copenhagen, DK)

09:45 - 09:50

Welcome and introduction

Dr. *Anne Lind Malte* and Dr. *Sine Voss David*

Departments of Clinical Biochemistry, Aarhus University Hospital, Aarhus Denmark, and Amager-Hvidovre Hospital, Hvidovre, Denmark

9:50-10:15

Clinical biochemistry at the molecular frontier: Connecting genomics, precision medicine, and people across disciplines and institutions

Chief Physician *Ole Halfdan Larsen*

Department of Molecular Medicine (MOMA), Aarhus University Hospital, Aarhus, Denmark

Advances in genomics and precision medicine depend not only on technology, but on creating environments where disciplines, institutions, and professional groups can work together. This talk explores the leadership role in providing such a host environment, enabling shared infrastructure, cross-boundary careers, and synergies between research, diagnostics, and patient care.

10:15 - 10:40

An alternative career path in the pharmaceutical industry – reflections on the transition from clinical chemistry

Medical Director *Elin Rebecka Carlsson*
Global Patient Safety, BioPharma, AstraZeneca, Sverige

HALL 3

09:45 - 11:15 SESSION 27

Preparedness for War and Crisis in Laboratory Medicine (Session by SFKK)

Chairs: TBA

TBA

TBA

TBA

Personal reflections on five years as a Patient Safety Physician at AstraZeneca and the transition from the hospital laboratory mid-Covid, after completed specialist training. What transferred, what did not, which were the real challenges – and what pharma roles suit a clinical chemistry background.

10:55 - 11:15

Choosing wisely – in practice

Clinical Director *Sidsel Rødgaard-Hansen*

Department of Clinical Biochemistry, Viborg Regional Hospital, Viborg, Denmark

10:40 - 11:05

From resident to chief physician – and why to pursue a career in management

Chief Physician *Rasmus Søgård Hansen*

Department of Clinical Diagnostics, University Hospital of Southern Denmark, Esbjerg, Denmark.

In this talk, I will take you through my path and share reflections on difficult choices and opportunities while navigating residency and family life. Career guidance is challenging, but I will try to outline possible career paths after completing specialist training in Clinical Biochemistry

11:05 - 11:15

Wrap-up and open discussion

MAIN HALL

11:30 - 12:15 PLENARY LECTURE

The future of healthcare – moving closer to the citizen

Chair: Senior Consultant *Birgitte Sandfeld Paulsen (Aalborg DK)*

Professor *Jakob Kjellberg*, VIVE – The Danish Center for Social Science Research, Denmark



Professor Jakob Kjellberg – a member of the Danish Health Structure Commission (“Sundhedsstrukturkommissionen”) – will share insights from the Commission’s work as a starting point for discussing the future development of Nordic healthcare systems. He will examine the necessary shift from hospital-based care towards community- and primary care-oriented solutions, addressing the magnitude of change required, the implications for clinical practice and laboratory medicine, and the opportunities and challenges in bringing healthcare closer to the citizen.

12:15 - 12:30 CLOSING CEREMONY